Epigenetic agents, including DNMT inhibitors (DNMTIs) and histone deacetylase (HDAC) inhibitors, have provided tremendous promise for the treatment of advanced, metastatic cancer by episensitization to overcome chemotherapy resistance53,54. This evidence concerns the gene HDAC9 and metastatic malignant neoplasm.